Inclusion Criteria:

- adult female patients

- at least two prior chemotherapies due to metastatic or inoperable breast cancer

- Karnofsky performance status of at least 60%

- pretreatment with at least one taxane and one anthracycline

Exclusion Criteria:

- previous treatment with mTOR-inhibitors, carboplatin, cisplatin or oxaliplatin

- inadequate organ function including bone marrow function

- bleeding tumours

- known uncontrolled metastases in CNS or carcinomatous meningosis

- patients who have been treated during the last five days with inhibitors or inducers
of CYP3A

- serious pulmonary, neurological, endocrinological or other disorders interfering with
this study medication, especially patients with known lung fibrosis, emphysema or
severe COPD